Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Rheuminations: Rheumatologists Seek Better Understanding of Fibrosing Disorders

Simon M. Helfgott, MD  |  Issue: December 2013  |  December 1, 2013

Skin Deep
“Still Glows” (glüht nach) by Paul Klee.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Helfgott
Dr. Helfgott

In its more aggravated forms, diffuse scleroderma is one of the most terrible of all human ills. Like Tithonus, to wither slowly, and like him to be beaten down and marred and wasted until one is literally a mummy, encased in an ever shrinking, slowly contracting skin of steel, is a fate not pictured in any tragedy, ancient or modern.

—Sir William Osler

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The pain passes but the beauty remains.

—Pierre-Auguste Renoir

The great 20th century Swiss painter Paul Klee might have benefitted from the care of a rheumatologist. A complex and enigmatic artist, he left behind a staggering 10,000 pieces of art at the time of his death in 1940. He constantly experimented with new techniques and styles, drawing squares, triangles, or domes using sun-splashed colors. He believed that the role of abstract art was to create the reality behind visible things.1

In 1933, dark clouds were amassing over Germany. Klee refused to declare his loyalty to the newly installed Nazi regime and was dismissed from his job. The persecution intensified, and his works were removed from private and public German collections. Seventeen of his paintings, along with others produced by Pablo Picasso, Edvard Munch, and Marc Chagall, were included in Joseph Goebbels’ infamous Entartete Kunst (Degenerate Art) show. The exhibition, which was viewed by millions of Germans, was designed to ridicule and denigrate creative art that did not uphold “correct” National Socialist virtues. Most of the exhibit was burned in the courtyard of a Berlin fire station, and some pieces were auctioned off to the highest bidders.2

It was around this time that Klee, who had fled to Bern, Switzerland, became ill. He developed severe fatigue and a skin rash that his physicians speculated was due to measles. However, this would have been a rather unlikely diagnosis in a 56-year-old male. An alternative interpretation has been offered by an expert on Klee, our colleague, John Varga, MD, the John and Nancy Hughes Distinguished Professor in rheumatology at Northwestern University in Chicago. He hypothesized that Klee’s facial rash was caused by an eruption of telangiectasia, the earliest sign of what became a full-blown case of scleroderma.2 Within months, this avid hiker experienced exertional dyspnea and worsening dysphagia that restricted his diet to liquids. In his letters, he described having arthritic pain in his hands, making it difficult to hold a paintbrush. As Klee’s health declined, his friends, Pablo Picasso and Georges Braque, came to pay homage. Despite being given the diagnosis of scleroderma, Paul Klee was not done painting.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:fibrosisPathogenesisRaynaud’s phenomenonSclerodermaSystemic sclerosis

Related Articles

    Capillaroscopy a Safe and Direct Method for SSc Diagnosis

    June 13, 2011

    Seeing vessels clearly can help with discovery and timely treatment

    Targeted Therapy for Scleroderma Fibrosis

    October 11, 2016

    Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a prevalence in North America of approximately 300 per 1 million people, SSc is associated with significant morbidity and high rates of mortality.1 Patients with scleroderma have four times greater mortality than age- and sex-matched controls, with…

    More Effective Antifibrotic Therapies for Systemic Sclerosis in Development; Adverse Events A Concern

    June 14, 2017

    Systemic sclerosis (SSc) is a rare disease affecting about 49,000 U.S. adults, and it is strongly associated with high levels of morbidity and mortality.1 Of the few available antifibrotic therapies, none is targeted for SSc. However, reason for optimism exists for antifibrotic treatments in early development and clinical trials, says Jörg H.W. Distler, MD, Heisenberg Professor…

    Labored Breathing

    January 1, 2007

    Strategies to diagnose and manage dyspnea in the scleroderma patient

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences